Comparison of effects of cyclosporine 0.05% and 0.1% in dry eye with Sjögren’s syndrome

Abstract Purpose To compare the effects of cyclosporine 0.05% and 0.1% in dry eye with Sjögren’s syndrome. Methods 120 eyes of 60 patients who have been diagnosed with Sjögren’s syndrome were retrospectively enrolled. Thirty patients (group 1, 60 eyes) were treated with cyclosporine 0.1% and 30 pati...

Full description

Saved in:
Bibliographic Details
Main Authors: Donghyun Jee, Su Yeon Han, Hyun Seung Kim, Eun Chul Kim
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Ophthalmology
Subjects:
Online Access:https://doi.org/10.1186/s12886-025-04173-x
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Purpose To compare the effects of cyclosporine 0.05% and 0.1% in dry eye with Sjögren’s syndrome. Methods 120 eyes of 60 patients who have been diagnosed with Sjögren’s syndrome were retrospectively enrolled. Thirty patients (group 1, 60 eyes) were treated with cyclosporine 0.1% and 30 patients (group 2, 60 eyes) with cyclosporine 0.05%. Ocular Surface Disease Index Questionnaire (OSDI), Schirmer I test, noninvasive tear break up time (NItBUT), corneal staining score, MMP 9, meibography, meibum quality and expressibility scores, tear meniscus height, and impression cytology were examined before treatment and at 1 and 3 months after treatment. Results All of dry eye signs and symptoms of both groups at 1 and 3 months were significantly improved compared with those before treatment, respectively (P < 0.05). OSDI, Schirmer I test, NItBUT, corneal and conunctival fluorescein score, MMP-9 grade, goblet cell density, and impression cytology grade of group1 were significantly improved compared with group 2 at 1 and 3 months after treatment (P < 0.05). The percentage of discontinued treatment in groups 1 and 2 was 26.7 and 3.3%, respectively. Conclusion Cyclosporine 0.1% was more effective for relieving inflammatory dry eye signs and symptoms but less tolerable compared with cyclosporine 0.05% in dry eye with Sjögren’s syndrome.
ISSN:1471-2415